Last reviewed · How we verify
A Single Center, Randomized, Double-blind Controlled Trial of Sitagliptin Versus Placebo to Reduce the Incidence and Severity of New-onset Diabetes After Kidney Transplant
The purpose of this study is to determine whether sitagliptin is effective in preventing the development of new-onset diabetes after kidney transplant (NODAT). Up to one-third of previously non-diabetic patients develop NODAT after a kidney transplant. Corticosteroids and calcineurin inhibitors are two commonly utilized anti-rejection medications that contribute to diabetes development through multiple mechanisms; including decreased insulin production by the pancreas. Sitagliptin is an oral medication that results in increased insulin secretion. We hypothesize that administration of sitagliptin to transplant recipients identified to be at risk for diabetes development will reduce the incidence and severity of NODAT.
Details
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 61 |
| Start date | 2013-09 |
| Completion | 2020-10 |
Conditions
- Posttransplant Diabetes Mellitus
Interventions
- Sitagliptin
- Placebo
Primary outcomes
- 2-hour Oral Glucose Tolerance Test-derived Blood Sugar — 3 months
Change in 2-hour OGTT-derived blood sugar will be measured at three months and again at six months. These are 3 month OGTT results
Countries
United States